These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 30578311)

  • 1. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
    Pérez-Garcia J; Cortés J; Metzger Filho O
    Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.
    Lobbezoo D; Truin W; Voogd A; Roumen R; Vreugdenhil G; Dercksen MW; van den Berkmortel F; Smilde T; van de Wouw A; van Kampen R; van Riel J; Peters N; Peer P; Tjan-Heijnen VC
    Oncotarget; 2016 May; 7(20):29412-9. PubMed ID: 27121067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
    Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
    Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
    Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
    Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
    Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
    Arpino G; Bardou VJ; Clark GM; Elledge RM
    Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
    García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
    Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
    Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
    Yardley DA; Shipley D; Zubkus J; Wright GL; Ward PJ; Mani A; Shastry M; Finney L; DeBusk L; Hainsworth JD
    Clin Breast Cancer; 2019 Feb; 19(1):1-9. PubMed ID: 30245148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.